Dallas, Nov 18 (Reuters) - An experimental antidote to the widely used blood clot preventer Pradaxa worked immediately and completely in an early-stage trial among healthy volunteers, raising hopes ...
Boehringer Ingelheim announced today that its experimental antidote, designed to stop the bleeding for blood thinner agent Pradaxa, has received a Breakthrough Therapy designation from the FDA—making ...
PR Newswire Boehringer Ingelheim Pharmaceuticals, Inc. RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug ...
Boehringer Ingelheim already had the FDA's "breakthrough" designation on idarucizumab, an antidote to its blockbuster anticoagulant Pradaxa. Now, the reversal agent has stepped on the agency's fast ...
Boehringer Ingelheim announced that the FDA has granted Breakthrough Therapy designation to idarucizumab, an investigational fully humanized antibody fragment (Fab), being evaluated as a specific ...
A new product which can rapidly reverse the effects of Boehringer Ingelheim's (BI) anticoagulant Pradaxa has been filed with regulators in the US and Europe. The drug, idarucizumab, is the first to be ...
Boehringer Ingelheim has inched closer to a Pradaxa antidote. The company announced Wednesday that it is set to launch its first-ever test among patients. The blood drug antidote, called idarucizumab, ...
Scientists say they're close to having a treatment that can quickly reverse the effects of the anti-clotting drug Pradaxa when necessary. Pradaxa is a new kind of blood thinner. It was approved by the ...
RIDGEFIELD, Conn., June 26, 2014 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback